Código QR (código de barras bidimensional)

CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients

Abstract Assessing the prognosis of patients with aggressive non-Hodgkin B cell lymphoma mainly relies on a clinical risk score (IPI). Standard first-line therapies are based on a chemo-immunotherapy with rituximab, which mediates CD16-dependent antibody-dependent cellular cytotoxicity (ADCC). We ph...

Fuld beskrivelse

Na minha lista:
Principais autores: Sylvia Zöphel, Nadja Küchler, Johanna Jansky, Cora Hoxha, Gertrud Schäfer, Julius J. Weise, Joanne Vialle, Lea Kaschek, Gebhard Stopper, Hermann Eichler, Daniela Yildiz, Alina Moter, Philipp Wendel, Evelyn Ullrich, Claudia Schormann, Torben Rixecker, Onur Cetin, Frank Neumann, Patrick Orth, Moritz Bewarder, Markus Hoth, Lorenz Thurner, Eva C. Schwarz
Format: Artigo
Sprog:Inglês
Udgivet: BMC 2024-09-01
Serier:Molecular Cancer
Fag:
aggressive B-NHL (non-Hodgkin B cell lymphoma)
diffuse large B cell lymphoma (DLBCL)
CD16+ T cell
CD16+ monocyte
antibody-dependent cellular cytotoxicity (ADCC)
rituximab
Online adgang:https://doi.org/10.1186/s12943-024-02123-7
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker